Anti-hepatitis Agents

Random Miscellaneous Quiz

Can you name the Anti-hepatitis Agents?

Quiz not verified by Sporcle

How to Play
Share
Tweet
Email
Embed
HintAnswer
Group MOA cont. (2) Ribonuclease L (activated by 2'5' oligo A): degrades mRNA.
P-kinetics: Lipophilic (pivoxil) moiety enhances oral bioavailability.
Contraindications: Hepatic decompensation, autoimmune dz, cardiac arrhythmia, pregnancy
Group MOA cont: Associated with mitochondrial DNA toxicity (by inhibiting DNA polymerase gamma)
Entecavir (Baraclude) Class
PEG-IFN α-2a/2b class
P-kinetics: Clinical resistance is rare. Oral bioavailability decreased by food (taken w/ empty stomach). Renal elimination (serum concentration increased w/ altered kidney activit
Group MOA: 3 major enzymes are activated by IFN-JNK/STAT signaling pathway: (1) 2',5' oligo A synthase: produces 2'5' oligo A.
SE: Anemia, neutropenia, dysgeusia, skin rash (esp. telaprevir), increased QT intervals (telaprevir)
Tenofovir Class
P-kinetics: Higher rate of complete response & less resistance vs. adefovir
Group P-kinetics: Pills once a day for a year or longer
Group MOA: Competively inhibit HBV DNA polymerase +/- incorporate into viral DNA causing chain termination. Phosphorylated to active forms intracellularly by cellular kinases.
IFN α-2b Class
P-kinetics: Synthetic (consensus). SC
Use: The most potent anti-HBV agent. Adults only
P-kinetics: Prolonged intracellular half-life in HBV (than in HIV). Rapid oral absorption; eliminated unchanged. Used at lower doses for hepatitis than for AIDS.
MOA: A prodrug (a guanosine nucleoside analogue). Phosphorylated by host cell enzymes; inhibits viral RNA-dependent polymerases.
P-kinetics:Oral bioavailability not affected by food. Emergence of resistance in long term use.
MOA: An adenosine analogue. Structurally similar to adefovir.
MOA: A thymidine analog
P-kinetics: Oral (TID). P450 substrates (potential rx interactions)
MOA: Serine protease inhibitors. Bind to inhibit HCV non-structural protein NS3
P-kinetics: Natural. SC or IM
PEG-IFN α-2a Class
HintAnswer
Telaprevir Class
MOA: A guanisine analog. Inhibits all 3 functions of HBV RNA-dependent DNA polymerase (base priming, reverse transcription of the -strand, synthesis of the + strand of HBV DNA.
Use: HBV: Safer for pts w/ decompensated liver dz. For both adults & peds
Telbivudine (Tyzeka) Class
Adefovir dipivoxil (Hepsera) Class
Use: Effective suppression of HBV DNA, normalization of ALT & reducing HBeAg. Adults only
Use: HBV treatment adults only
SE: Dose-dependent hemolytic anemia. Depression, fatigue, irritability, nausea, insomnia.
Boceprevir Class
MOA: A prodrug of adefovir (adenosine analogue). Slows suppression of HBV DNA; least seroconversion
IFN alfacon-1 class
SE: Increased pancreatitis in HIV/HBV pts. Emergence of resistance (mutations of DNA polymerase)
Use: Improve therapeutic response in pts (>18 yo) w/ HCV genotype 1 when combined w/ IFN/ribavirin
P-kinetics: Oral bioavailability increased with high-fat meal, decreased with antacid.
SE: HA, fatigue, nausea. Potential mitochondrial toxicity (lactic acidosis & hepatic steatosis)
SE: Flu-like symptoms (fever, chills, myalgias, malaise). Neurotoxicity, myelosuppression, fatigue (chronic use). Transient hepatic enzyme elevation.
IFN α-2a/2b class
Use: Lamivudine-resistant HBV. Adults only
Drug MOA: PEG = polyethylene glycol
Contraindications: Pts w/ uncorrected anemia, ESRD, preggo. Teratogenic: avoid pregnancy for > 6 mos thereafter
MOA: A cytosine analogue
Group MOA cont. (3) Protein kinase (activated by dsRNA): phosphorylates/inhibits eIF-2, therefore blocking PRO synthesis
SE: Nephrotoxicity (at high doses). Potential mitochondrial DNA toxicity
Lamivudine (3TC, Heptovir) Class
P-kinetics: Slower clearance (less frequent dosing). Dosage adjustment is needed in renal dysfunction

You're not logged in!

Compare scores with friends on all Sporcle quizzes.
Sign Up with Email
OR
Log In

You Might Also Like...

Show Comments

Extras